Companies › Baxalta now part of Shire
1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Jan 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AskBio009 (BAX 335) Adeno-associated virus serotype 8 (AAV8) delivering Factor IX (FIX) gene therapy | F9 | Phase 1 | Hemophilia B | Jan 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01687608 | AskBio009 (BAX 335) | Phase 1 | Hemophilia B | Hematology | Jan 2030 |
CSL Behring BioMarin Pharmaceutical Pfizer Roche Shanghai Xinzhi BioMed IntraBio Biocad Regeneron Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.